Drugmakers agree to six-month DTC delay

Under fire over direct-to-consumer ads, which some Congressional legislators contend are misleading to consumers, pharmaceutical companies have agreed to voluntarily wait six months after drugs are approved before advertising to the public. The Congressmen pressuring the drug companies--Bart Stupak (D-MI) and John Dingell (D-MI)--aren't pleased, however, given that what they wanted was a two year DTC moratorium. Besides, even the drug companies themselves admit that they generally don't advertise within the first six months after product introductions anyway, given that they usually spend at least that much time educating doctors about drugs before beginning consumer advertising. Meanwhile, the pharmas turned down other requests, including that they only advertise products when studies have shown that they improve clinical outcomes (rather than having used biomarkers). (Looks like they gave up a whole lot of nothing, in other words.) The promise to delay on DTC advertising came as part of a hearing focused on ads for Pfizer's Lipitor, Johnson & Johnson's Procrit, and Merck/Schering-Plough's cholesterol drug Vytorin.

To learn more about the hearing:
- read this Wall Street Journal blog item

Related Articles:
Who will pay for DTC pharma ad oversight?
Drugmakers face direct-to-consumer ad ban
AMA to study the impact of drug advertising

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.